Mitochondrial Dysfunction Induced by Nuclear Poly(ADP-Ribose) Polymerase-1: A Treatable Cause of Cell Death in Stroke

Translational Stroke Research

Volumn 5, Issue 1, 2014, Pages 136-144

  Baxter, Paul ^a   Chen, Yanting ^a,b   Xu, Yun ^b   Swanson, Raymond A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Apoptosis inducing factor; Ischemia; Mitochondrial depolarization; Mitochondrial permeability transition; Poly(ADP ribose) polymerase 1

Indexed keywords

1,4 BUTANEDIOL; 4 HYDROXYBUTYRIC ACID; KETONE BODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1;

AEROBIC METABOLISM; BRAIN ISCHEMIA; CELL DEATH; CELL FATE; CEREBROVASCULAR ACCIDENT; DEPOLARIZATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; HUMANS; MICE; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; POLY(ADP-RIBOSE) POLYMERASES; PYRUVIC ACID; RATS; STROKE;

EID: 84893812229     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-013-0283-0     Document Type: Review

References (90)

1. Choi DW. Excitotoxic cell death. J Neurobiol. 1992;23(9): 1261-76.
2. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010;460(2): 525-42.
3. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature. 2000;403(6767): 316-21.
4. Gouix E, Leveille F, Nicole O, Melon C, Had-Aissouni L, Buisson A. Reverse glial glutamate uptake triggers neuronal cell death through extrasynaptic NMDA receptor activation. Mol Cell Neurosci. 2009;40(4): 463-73.
5. Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of N-methyl-d-aspartate receptors may protect against ischemic damage in the brain. Science. 1984;226(4676): 850-2.
6. Gill R, Foster AC, Woodruff GN. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci. 1987;7(10): 3343-9.
7. Ozyurt E, Graham DI, Woodruff GN, McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab. 1988;8(1): 138-43.
8. Steinberg GK, George CP, DeLaPaz R, Shibata DK, Gross T. Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. Stroke. 1988;19(9): 1112-8.
9. Steinberg GK, Saleh J, Kunis D, DeLaPaz R, Zarnegar SR. Protective effect of N-methyl-d-aspartate antagonists after focal cerebral ischemia in rabbits. Stroke. 1989;20(9): 1247-52.
10. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat. Ann Neurol. 1988;24(4): 543-51.
11. Olney JW, Ikonomidou C, Mosinger JL, Frierdich G. MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain. J Neurosci. 1989;9(5): 1701-4.
12. Diemer NH, Johansen FF, Benveniste H, Bruhn T, Berg M, Valente E, et al. Ischemia as an excitotoxic lesion: protection against hippocampal nerve cell loss by denervation. Acta Neurochir Suppl (Wien). 1993;57: 94-101.
13. Morikawa E, Mori H, Kiyama Y, Mishina M, Asano T, Kirino T. Attenuation of focal ischemic brain injury in mice deficient in the epsilon1 (NR2A) subunit of NMDA receptor. J Neurosci. 1998;18(23): 9727-32.
14. Aarts M, Liu Y, Liu L, Besshoh S, Arundine M, Gurd JW, et al. Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science. 2002;298(5594): 846-50.
15. Dawson DA, Graham DI, McCulloch J, Macrae IM. Anti-ischaemic efficacy of a nitric oxide synthase inhibitor and a N-methyl-d-aspartate receptor antagonist in models of transient and permanent focal cerebral ischaemia. Br J Pharmacol. 1994;113(1): 247-53.
16. Gill R, Brazell C, Woodruff GN, Kemp JA. The neuroprotective action of dizocilpine (MK-801) in the rat middle cerebral artery occlusion model of focal ischaemia. Br J Pharmacol. 1991;103(4): 2030-6.
17. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology. 2008;55(3): 363-89.
18. Swan JH, Meldrum BS. Protection by NMDA antagonists against selective cell loss following transient ischaemia. J Cereb Blood Flow Metab. 1990;10(3): 343-51.
19. Steinberg GK, Panahian N, Perez-Pinzon MA, Sun GH, Modi MW, Sepinwall J. Narrow temporal therapeutic window for NMDA antagonist protection against focal cerebral ischaemia. Neurobiol Dis. 1995;2(2): 109-18.
20. Hill MD, Martin RH, Mikulis D, Wong JH, Silver FL, Terbrugge KG, et al. Safety and efficacy of NA-1 in patients with iatrogenic stroke after endovascular aneurysm repair (ENACT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;11(11): 942-50.
21. Simon RP, Griffiths T, Evans MC, Swan JH, Meldrum BS. Calcium overload in selectively vulnerable neurons of the hippocampus during and after ischemia: an electron microscopy study in the rat. J Cereb Blood Flow Metab. 1984;4(3): 350-61.
22. Susin SA, Zamzami N, Kroemer G. Mitochondria as regulators of apoptosis: doubt no more. Biochim Biophys Acta. 1998;1366(1-2): 151-65.
23. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev. 2000;80(1): 315-60.
24. Sims NR, Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta. 2010;1802(1): 80-91.
25. Nicholls DG. Mitochondria and calcium signaling. Cell Calcium. 2005;38(3-4): 311-7.
26. Vesce S, Kirk L, Nicholls DG. Relationships between superoxide levels and delayed calcium deregulation in cultured cerebellar granule cells exposed continuously to glutamate. J Neurochem. 2004;90(3): 683-93.
27. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4): 239-57.
28. Krajewski S, Krajewska M, Ellerby LM, Welsh K, Xie Z, Deveraux QL, et al. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc Natl Acad Sci U S A. 1999;96(10): 5752-7.
29. Giffard RG, Swanson RA. Ischemia-induced programmed cell death in astrocytes. Glia. 2005;50(4): 299-306.
30. Regan RF, Panter SS, Witz A, Tilly JL, Giffard RG. Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res. 1995;705(1-2): 188-98.
31. MacManus JP, Buchan AM. Apoptosis after experimental stroke: fact or fashion? J Neurotrauma. 2000;17(10): 899-914.
32. Chauvier D, Renolleau S, Holifanjaniaina S, Ankri S, Bezault M, Schwendimann L, et al. Targeting neonatal ischemic brain injury with a pentapeptide-based irreversible caspase inhibitor. Cell Death Dis. 2011;2: e203.
33. Gill R, Soriano M, Blomgren K, Hagberg H, Wybrecht R, Miss MT, et al. Role of caspase-3 activation in cerebral ischemia-induced neurodegeneration in adult and neonatal brain. J Cereb Blood Flow Metab. 2002;22(4): 420-30.
34. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers GM, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999;397(6718): 441-6.
35. David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed). 2009;14: 1116-28.
36. Wang X, Yang C, Chai J, Shi Y, Xue D. Mechanisms of AIF-mediated apoptotic DNA degradation in Caenorhabditis elegans. Science. 2002;298(5598): 1587-92.
37. + depletion and mitochondrial permeability transition. J Biol Chem. 2004;279(18): 18895-902.
38. Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, Geley S, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J Exp Med. 1997;186(1): 25-37.
39. Rasola A, Bernardi P. Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium. 2011;50(3): 222-33.
40. Bernardi P. The mitochondrial permeability transition pore: a mystery solved? Front Physiol. 2013;4: 95.
41. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta. 1998;1366(1-2): 177-96.
42. Longuemare MC, Hill MP, Swanson RA. Glycolysis can prevent non-synaptic excitatory amino acid release during hypoxia. Neuroreport. 1994;5(14): 1789-92.
43. Swanson RA, Chen J, Graham SH. Glucose can fuel glutamate uptake in ischemic brain. J Cereb Blood Flow Metab. 1994;14(1): 1-6.
44. MacMillan VH. Cerebral energy metabolism in cyanide encephalopathy. J Cereb Blood Flow Metab. 1989;9(2): 156-62.
45. Obrenovitch TP. The ischaemic penumbra: twenty years on. Cerebrovasc Brain Metab Rev. 1995;7(4): 297-323.
46. Shiraishi K, Sharp FR, Simon RP. Sequential metabolic changes in rat brain following middle cerebral artery occlusion: a 2-deoxyglucose study. J Cereb Blood Flow Metab. 1989;9(6): 765-73.
47. Lowry OH, Passonneau JV, Hasselberger FH, Schultz DW. Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain. J Biol Chem. 1964;239: 18-30.
48. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342(Pt 2): 249-68.
49. de Murcia G, Schreiber V, Molinete M, Saulier B, Poch O, Masson M, et al. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem. 1994;138(1-2): 15-24.
50. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3): 375-429.
51. Dugan LL, Sensi SL, Canzoniero LM, Handran SD, Rothman SM, Lin TS, et al. Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-d-aspartate. J Neurosci. 1995;15(10): 6377-88.
52. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271(5 Pt 1): C1424-37.
53. Bindokas VP, Jordan J, Lee CC, Miller RJ. Superoxide production in rat hippocampal neurons: selective imaging with hydroethidine. J Neurosci. 1996;16(4): 1324-36.
54. Mandir AS, Poitras MF, Berliner AR, Herring WJ, Guastella DB, Feldman A, et al. NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase. J Neurosci. 2000;20(21): 8005-11.
55. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase. J Cereb Blood Flow Metab. 1997;17(11): 1143-51.
56. Pieper AA, Verma A, Zhang J, Snyder SH. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci. 1999;20(4): 171-81.
57. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J, et al. Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med. 1997;3(10): 1089-95.
58. Moroni F, Meli E, Peruginelli F, Chiarugi A, Cozzi A, Picca R, et al. Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ. 2001;8(9): 921-32.
59. Strosznajder RP, Gadamski R, Czapski GA, Jesko H, Strosznajder JB. Poly(ADP-ribose) polymerase during reperfusion after transient forebrain ischemia: its role in brain edema and cell death. J Mol Neurosci. 2003;20(1): 61-72.
60. Suh SW, Gum ET, Hamby AM, Chan PH, Swanson RA. Hypoglycemic neuronal death is triggered by glucose reperfusion and activation of neuronal NADPH oxidase. J Clin Invest. 2007;117(4): 910-8.
61. Suh SW, Hamby AM, Swanson RA. Hypoglycemia, brain energetics, and hypoglycemic neuronal death. Glia. 2007;55(12): 1280-6.
62. Suh SW, Aoyama K, Chen Y, Garnier P, Matsumori Y, Gum E, et al. Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J Neurosci. 2003;23(33): 10681-90.
63. Szabo C, Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci. 1998;19(7): 287-98.
64. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res. 1985;101(1): 4-15.
65. + and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem. 2001;276(4): 2571-5.
66. Alano CC, Tran A, Tao R, Ying W, Karliner JS, Swanson RA. Differences among cell types in NAD(+) compartmentalization: a comparison of neurons, astrocytes, and cardiac myocytes. J Neurosci Res. 2007.
67. Ying W, Chen Y, Alano CC, Swanson RA. Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J Cereb Blood Flow Metab. 2002;22(7): 774-9.
68. + repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem Biophys Res Commun. 2003;308(4): 809-13.
69. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 2004;18(11): 1272-82.
70. Verrax J, Vanbever S, Stockis J, Taper H, Calderon PB. Role of glycolysis inhibition and poly(ADP-ribose) polymerase activation in necrotic-like cell death caused by ascorbate/menadione-induced oxidative stress in K562 human chronic myelogenous leukemic cells. Int J Cancer. 2007;120(6): 1192-7.
71. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A. 2006;103(48): 18314-9.
72. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M, et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A. 2006;103(48): 18308-13.
73. + depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci. 2010;30(8): 2967-78.
74. Suh SW, Aoyama K, Matsumori Y, Liu J, Swanson RA. Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment. Diabetes. 2005;54(5): 1452-8.
75. Yu YM, Kim JB, Lee KW, Kim SY, Han PL, Lee JK. Inhibition of the cerebral ischemic injury by ethyl pyruvate with a wide therapeutic window. Stroke. 2005. pp. 2238-43.
76. Vergoni AV, Ottani A, Botticelli AR, Zaffe D, Guano L, Loche A, et al. Neuroprotective effect of gamma-hydroxybutyrate in transient global cerebral ischemia in the rat. Eur J Pharmacol. 2000;397(1): 75-84.
77. Lee JY, Kim YH, Koh JY. Protection by pyruvate against transient forebrain ischemia in rats. J Neurosci. 2001;21(20): RC171.
78. Suzuki M, Suzuki M, Kitamura Y, Mori S, Sato K, Dohi S, et al. Beta-hydroxybutyrate, a cerebral function improving agent, protects rat brain against ischemic damage caused by permanent and transient focal cerebral ischemia. Jpn J Pharmacol. 2002;89(1): 36-43.
79. Ottani A, Saltini S, Bartiromo M, Zaffe D, Renzo Botticelli A, Ferrari A, et al. Effect of gamma-hydroxybutyrate in two rat models of focal cerebral damage. Brain Res. 2003;986(1-2): 181-90.
80. Gonzalez-Falcon A, Candelario-Jalil E, Garcia-Cabrera M, Leon OS. Effects of pyruvate administration on infarct volume and neurological deficits following permanent focal cerebral ischemia in rats. Brain Res. 2003;990(1-2): 1-7.
81. Sadasivan S, Maher TJ, Quang LS. Gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL), and 1, 4-butanediol (1, 4-BD) reduce the volume of cerebral infarction in rodent transient middle cerebral artery occlusion. Ann N Y Acad Sci. 2006;1074: 537-44.
82. Yi JS, Kim TY, Kyu Kim D, Koh JY. Systemic pyruvate administration markedly reduces infarcts and motor deficits in rat models of transient and permanent focal cerebral ischemia. Neurobiol Dis. 2007;26(1): 94-104.
83. Sharma AB, Barlow MA, Yang SH, Simpkins JW, Mallet RT. Pyruvate enhances neurological recovery following cardiopulmonary arrest and resuscitation. Resuscitation. 2008;76(1): 108-19.
84. Gao B, Kilic E, Baumann CR, Hermann DM, Bassetti CL. Gamma-hydroxybutyrate accelerates functional recovery after focal cerebral ischemia. Cerebrovasc Dis. 2008;26(4): 413-9.
85. Wang Q, van Hoecke M, Tang XN, Lee H, Zheng Z, Swanson RA, et al. Pyruvate protects against experimental stroke via an anti-inflammatory mechanism. Neurobiol Dis. 2009;36(1): 223-31.
86. Martín A, Rojas S, Perez-Asensio F, Planas AM. Transient benefits but lack of protection by sodium pyruvate after 2-hour middle cerebral artery occlusion in the rat. Brain Res. 2009;1272: 45-51.
87. Shen H, Hu X, Liu C, Wang S, Zhang W, Gao H, et al. Ethyl pyruvate protects against hypoxic-ischemic brain injury via anti-cell death and anti-inflammatory mechanisms. Neurobiol Dis. 2010;37(3): 711-22.
88. Pan R, Rong Z, She Y, Cao Y, Chang LW, Lee WH. Sodium pyruvate reduces hypoxic-ischemic injury to neonatal rat brain. Pedtr res. 2012;72(5): 479-89.
89. Xu K, Lamanna JC, Puchowicz MA. Neuroprotective properties of ketone bodies. Adv exp med biol. 2012;737: 97-102.
90. Ryou MG, Liu R, Ren M, Sun J, Mallet RT, Yang SH. Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway. Stroke. 2012;43(4): 1101-7.